Key result
Cardiac Myosin Inhibitors, particularly mavacamten and aficamten, have emerged as a transformative treatment for symptomatic hypertrophic cardiomyopathy by addressing sarcomeric hypercontractility.
Why the study?
Do Cardiac Myosin Inhibitors improve outcomes in patients with symptomatic Hypertrophic Cardiomyopathy?
Do Cardiac Myosin Inhibitors improve outcomes in patients with symptomatic Hypertrophic Cardiomyopathy?
Cardiac Myosin Inhibitors (mavacamten and aficamten) have transformed the management of symptomatic Hypertrophic Cardiomyopathy by directly addressing sarcomeric hypercontractility.
In recent years, we have witnessed a significant shift in the management of symptomatic Hypertrophic Cardiomyopathy (HCM). For decades, treatment relied on medications that provided hemodynamic support without directly addressing sarcomeric hypercontractility, the primary pathophysiological driver of the disease. The emergence of Cardiac Myosin Inhibitors (CMIs), particularly mavacamten and aficamten, has transformed this landscape., In an article published in this issue of the International Journal of Cardiovascular Sciences, Fogaça PHT et al. present an updated systematic review and meta-analysis that [...]
No takes yet. Share an insight, caveat, or question.
Bittencourt et al. (2026) conducted an editorial in Hypertrophic Cardiomyopathy. Cardiac Myosin Inhibitors was evaluated. Cardiac Myosin Inhibitors, particularly mavacamten and aficamten, have emerged as a transformative treatment for symptomatic hypertrophic cardiomyopathy by addressing sarcomeric hypercontractility.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: